RAMP1 and neoplasm: In head and neck squamous cell carcinoma (HNSCC) and melanoma, our research has shown that tumor-innervating nociceptors modulate anti-tumor immunity through the release of calcitonin gene-related peptide (CGRP) and its interaction with receptor activity-modifying protein 1 (RAMP1).